普利制药注射用比伐芦定在沙特阿拉伯获批上市

Core Viewpoint - Recently, the company received a marketing authorization from the Saudi Arabian Food and Drug Authority for injectable bivalirudin (specification: 250mg), enabling it to sell this product in Saudi Arabia, which is expected to positively impact the company's expansion into the Middle Eastern market [1] Company Summary - The company has obtained the necessary approval to market injectable bivalirudin in Saudi Arabia, indicating a significant step in its international growth strategy [1] - This approval allows the company to tap into the Middle Eastern pharmaceutical market, potentially increasing its revenue and market presence in the region [1]